Parallax Volatility Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Parallax Volatility Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-316,300	Closed	-$9.87M	–	1826
2025 Q4	$9.87M	Buy	316,300 +250,000	+377%	+$6.16M	0.02%	463
2025 Q3	$1.34M	Sell	66,300 -20,000	-23%	-$351K	﹤0.01%	1040
2025 Q2	$1.45M	Buy	86,300 +20,000	+30%	+$323K	﹤0.01%	977
2025 Q1	$1.02M	Sell	66,300 -741,900	-92%	-$13.3M	﹤0.01%	1039
2024 Q4	$17.8M	Buy	808,200 +78,700	+11%	+$1.43M	0.03%	374
2024 Q3	$13.1M	Buy	729,500 +198,000	+37%	+$3.47M	0.02%	453
2024 Q2	$8.64M	Buy	531,500 +214,300	+68%	+$3.3M	0.02%	528
2024 Q1	$4.48M	Buy	317,200 +266,600	+527%	+$3.36M	0.01%	768
2023 Q4	$528K	Sell	50,600 -258,000	-84%	-$2.41M	﹤0.01%	1582
2023 Q3	$3.15M	Sell	308,600 -646,600	-68%	-$6.02M	0.01%	930
2023 Q2	$7.19M	Buy	955,200 +135,100	+16%	+$1.1M	0.02%	641
2023 Q1	$7.26M	Sell	820,100 -5,700	-0.7%	-$56.4K	0.01%	699
2022 Q4	$7.53M	Buy	825,800 +232,700	+39%	+$2.03M	0.01%	882
2022 Q3	$4.79M	Sell	593,100 -801,200	-57%	-$7.08M	0.01%	1037
2022 Q2	$10.5M	Sell	1,394,300 -100,700	-7%	-$877K	0.01%	708
2022 Q1	$14M	Buy	1,495,000 +119,600	+9%	+$998K	0.01%	628
2021 Q4	$11M	Buy	1,375,400 +406,300	+42%	+$3.67M	0.01%	570
2021 Q3	$9.44M	Sell	969,100 -241,700	-20%	-$2.26M	0.01%	665
2021 Q2	$12M	Buy	+1,210,800	New	+$12.8M	0.02%	480
2021 Q1	–	Sell	-253,500	Closed	-$2.45M	–	2110
2020 Q4	$2.45M	Sell	253,500 -95,900	-27%	-$919K	﹤0.01%	1195
2020 Q3	$3.15M	Sell	349,400 -99,600	-22%	-$1.05M	﹤0.01%	1520
2020 Q2	$5.53M	Buy	449,000 +85,300	+23%	+$965K	0.01%	1035
2020 Q1	$3.27M	Buy	363,700 +148,100	+69%	+$1.52M	﹤0.01%	1041
2019 Q4	$2.11M	Sell	215,600 -676,800	-76%	-$6.04M	﹤0.01%	1241
2019 Q3	$6.14M	Buy	892,400 +253,400	+40%	+$1.94M	0.01%	742
2019 Q2	$5.9M	Buy	639,000 +159,100	+33%	+$1.92M	0.01%	670
2019 Q1	$7.52M	Buy	479,900 +20,300	+4%	+$358K	0.01%	557
2018 Q4	$7.09M	Buy	459,600 +143,500	+45%	+$2.94M	0.01%	617
2018 Q3	$6.81M	Buy	+316,100	New	+$7.34M	0.01%	605
2018 Q2	–	Sell	-30,000	Closed	-$513K	–	3266
2018 Q1	$513K	Sell	30,000 -170,000	-85%	-$3.32M	﹤0.01%	1118
2017 Q4	$3.79M	Buy	200,000 +100,000	+100%	+$1.5M	0.01%	690
2017 Q3	$1.76M	Buy	+100,000	New	+$2.25M	﹤0.01%	887
2016 Q4	–	Sell	-80,000	Closed	-$3.68M	–	4126
2016 Q3	$3.68M	Buy	+80,000	New	+$4.17M	0.01%	796
2016 Q1	–	Sell	-40,000	Closed	-$2.63M	–	3644
2015 Q4	$2.63M	Sell	40,000 -9,600	-19%	-$593K	0.01%	919
2015 Q3	$2.8M	Sell	49,600 -181,700	-79%	-$11.8M	0.01%	868
2015 Q2	$13.7M	Buy	231,300 +156,900	+211%	+$9.68M	0.03%	390
2015 Q1	$4.63M	Sell	74,400 -42,800	-37%	-$2.49M	0.01%	740
2014 Q4	$6.74M	Sell	117,200 -131,600	-53%	-$7.33M	0.02%	597
2014 Q3	$13.4M	Buy	+248,800	New	+$13.2M	0.04%	360
2014 Q1	–	Sell	-300	Closed	-$12K	–	3689
2013 Q4	$12K	Hold	300	–	–	﹤0.01%	2905
2013 Q3	$11K	Hold	300	–	–	﹤0.01%	2553
2013 Q2	$12K	Buy	+300	New	+$11.7K	﹤0.01%	2182

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallax Volatility Advisers's TEVA Position: Q1 2026 in Review

Parallax Volatility Advisers sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 117,708 shares — an estimated $3.67M sold.

Parallax Volatility Advisers first reported a position in TEVA in Q1 2014 and held it in 38 quarters. The position peaked at $25M in Q4 2024. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Parallax Volatility Advisers reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Parallax Volatility Advisers sold 117,708 Teva Pharmaceuticals shares in Q1 2026, an estimated $3.67M.
Parallax Volatility Advisers first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 38 quarters.
Parallax Volatility Advisers's Teva Pharmaceuticals position peaked at $25M in Q4 2024.
651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.